Intel Corp vs McKesson Corporation — how do they compare? Intel Corp trades at $105.8 (market cap $487.82B), while McKesson Corporation trades at $832.45 (market cap $97.35B). The key difference: Intel Corp is far larger — about 5× McKesson Corporation's market cap, and Intel Corp pays the higher dividend (2.24%). Which is the better fit depends on your goals.
| INTC | MCK | |
|---|---|---|
Market Cap | $487.82B | $97.35B |
Volume | 43,552,012 | — |
Sector | Technology | Health |
52-Week High | $140.94 | $995.69 |
52-Week Low | $19.31 | $659.01 |
Enterprise Value | $500.07B | $101.98B |
Dividend Yield | 2.24% | 0.39% |
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $105.45, up 10.95% on the day, showing strong momentum ahead of Q2 2026 earnings. The stock exhibits a bearish technical signal but has beaten EPS estimates for three consecutive quarters. Revenue remains stable around $53B, though net income turned negative in 2025. Recent news highlights optimism around data center and AI segment growth, with a new partnership with Fortinet for security chips announced on July 21, 2026.
The outlook is mixed: analyst consensus suggests modest upside to a $110.33 price target, but high valuation ratios (P/E 904.17) and negative profitability metrics pose risks. Key catalysts include Q2 earnings results and execution of the turnaround strategy under CEO Lip-Bu Tan, while competitive pressures from Nvidia and AMD remain headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →